SI-BONE's innovative approach fuels both EBITDA gains and increased revenue
- SI-BONE reported Q3 2025 adjusted EBITDA of $2. 3M and raised full-year revenue guidance to $198M–$200M. - Gross margin expanded to 79.8%, while operating losses narrowed by 29.5% despite 11.9% higher operating expenses. - Cash reserves remained stable at $145.7M, with CEO citing growth from minimally invasive solutions and global expansion. - Analysts highlight innovation and expanded indications as key drivers for future orthopedic market share gains.
On November 10, 2025, SI-BONE, Inc. (NASDAQ: SIBN) announced its third-quarter 2025 financial results, surpassing expectations with a positive adjusted EBITDA and an updated annual revenue outlook now ranging from $198 million to $200 million. The company, recognized worldwide for its sacropelvic disorder solutions, also revealed plans for a conference call to provide a detailed review of its latest performance.
Gross margin improved to 79.8% in the third quarter of 2025, an increase of 75 basis points from 79.1% in the same quarter last year, attributed to enhanced operational efficiency. Operating expenses climbed by 11.9% to $44.2 million, reflecting expanded commercial efforts for new product introductions and higher administrative spending. Despite these increases, the operating loss was reduced by 29.5% to $5.4 million, and net loss narrowed by 30.6% to $4.6 million, or $0.11 per diluted share, compared to $6.6 million, or $0.16 per share, a year earlier.
As of September 30, 2025, SI-BONE’s cash balance stood at $145.7 million, unchanged from the prior quarter. The company raised its full-year 2025 outlook, now expecting revenue to grow by 18-20% to between $198 million and $200 million, while maintaining a gross margin near 79.5%. These projections highlight the company’s confidence in its market standing, with CEO David B. Robinson crediting the results to “the ongoing adoption of our minimally invasive solutions” and the company’s expanding international presence.
The updated outlook demonstrates SI-BONE’s ability to thrive in a challenging healthcare environment. Since introducing minimally invasive sacroiliac joint procedures in 2009, the company has enabled more than 4,900 physicians to perform over 135,000 surgeries. Industry analysts point out that SI-BONE’s emphasis on innovation and broadening the use of its technologies positions it well to further increase its share in the orthopedic market.
A live webcast and conference call to review the financial results will take place on November 10, 2025, at 4:30 p.m. Eastern Time. The event will be accessible for at least 90 days afterward, with live audio streaming available on SI-BONE’s investor relations website.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Hassett’s Perspective on the Fed: Bold Rate Reductions or Fundamental Overhaul
- Kevin Hassett, Trump's top economic adviser, proposes Fed chairmanship with plans to cut interest rates and restructure the central bank's research and communication strategies. - He advocates reducing Fed staff influence and adopting top-down decision-making, aligning with Trump's skepticism of institutional expertise while claiming nonpartisan leadership. - Hassett warns a 40-day government shutdown risks pushing Q4 GDP negative, emphasizing fiscal-monetary coordination amid economic uncertainty and st
AAVE Rises 0.86% as Large Investors Accumulate and Aave Founder Criticizes BoE
- AAVE rose 0.86% in 24 hours to $205.44 amid whale accumulation and regulatory scrutiny, despite 32.98% annual declines. - Major on-chain actors borrowed $180M+ from Aave to purchase 388,615 ETH ($1.32B), leveraging DeFi protocols for ETH accumulation. - Whale strategies maintain 2.1 leverage ratios, while backtests show Aave whale activity correlates weakly with sustained AAVE price gains. - Analysis suggests whale accumulation may signal distribution or liquidity provision rather than bullish price mome
SOL Price Forecast for 2025: Network Enhancements and Growing Institutional Interest Drive Positive Outlook
- Solana's 2025-2026 roadmap includes Firedancer, ZK Compression v2, and Alpenglow upgrades to boost scalability, reduce fees, and enable real-time applications. - Institutional adoption surges with $841M+ SOL holdings, $817M in ETF assets, and partnerships with Visa/R3 enhancing its financial infrastructure utility. - Price resilience defies market trends as TVL triples to $40B, driven by ETF inflows and DeFi growth despite 30% Q3 user declines. - Analysts project $147-$494 price range for 2025, citing 26
Ethereum News Update: Separating Hype from Reality—Crypto Market Shifts as BlockDAG, Ethereum, and XRP Aim for Leadership by 2026
- BlockDAG's $435M presale and hybrid DAG/Proof-of-Work model position it as a top 2026 growth candidate with 3.5M active miners. - Ethereum faces technical risks like potential death cross but retains 53% stablecoin dominance through JPMorgan/BlackRock partnerships. - XRP shows $2.40 recovery amid Bitcoin ETF inflows but needs sustained confidence to maintain $3.95B derivatives open interest. - Market shifts toward projects with institutional validation (CertiK audits) and real-world adoption (Seattle spo
